Contact SCGE




Clinical Trial Report

Gene Therapy Trial Report

Summary

Open-laBel Dose-escalation Study for CRISPR/cas13- Rna TargetInG THerapy for the Treatment of Neovascular Age-related Macular Degeneration in Phase I Trial


NCTID NCT06623279 (View at clinicaltrials.gov)
Description
Development Status Active
Indication Neovascular Age-Related Macular Degeneration (nAMD)
Disease Ontology Term DOID:10871
Compound Name HG202
Sponsor HuidaGene Therapeutics Co., Ltd.
Funder Type Industry
Recruitment Status
Not yet recruiting
Enrollment Count 15
Results Posted Not Available

Therapy Information


Target Gene/Variant VEGFA mRNA
Therapy Type Gene editing
Therapy Route In-vivo
Mechanism of Action Gene inactivation
Route of Administration Subretinal
Drug Product Type Viral vector
Target Tissue/Cell
Delivery System Viral transduction
Vector Type AAV
Editor Type hfCas13Y
Dose 1 Undisclosed low dose
Dose 2 Undisclosed medium dose
Dose 3 Undisclosed high dose
Dose 4
Dose 5

Study Record Dates


Current Stage Phase1
Submit Date 2024-09-30
Completion Date 2031-02-01
Last Update 2024-10-02

Participation Criteria


Eligible Age 50 Years - 85 Years
Standard Ages Adult, Older adult
Sexes Eligible for Study ALL

Locations


No.of Trial Sites
Locations

Regulatory Information


Has US IND True
FDA Designations
Recent Updates FDA cleared IND November 2024

Resources/Links